NEW YORK (GenomeWeb) – In a filing with the US Securities and Exchange Commission this week, Thermo Fisher Scientific reported it recorded $90 million in restructuring and other costs related to its acquisition of Affymetrix. That expense included $11 million for the sale of inventories revalued at the date of acquisition and to conform the accounting policies of Affymetrix with Thermo Fisher's own accounting policies, and $29 million for third-party transaction costs.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.